Key Drivers
- Strong liquidity
- Very high gross margin
- Large operating losses
AIAI Summary
STAAR's investment thesis has shifted from a pure ICL adoption story to a governance-and-capital-allocation call where activist-backed insider buying and management moves make near-term reduction in SG&A and measurable FCF improvement (within 2–4 quarters) the decisive catalyst for upside. Monitor quarterly FCF, SG&A as a percent of sales, and activist/board actions—failure to show clear operating-leverage progress materially raises dilution and downside risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Very high gross margin
- •Large operating losses
STAA has strong liquidity and very high gross margins but is generating significant operating/net losses, negative cash flow and poor returns despite low leverage.
Price Behavior
Key Price Behavior Insights:
- •Price below average
- •RSI neutral
- •Elevated volatility
Short-term trend mildly negative: price below its last-month average with RSI ~61 signaling neutral momentum, near-term support at ~$17.20 (deeper $16.10–$16.20) and resistance in the high-teens–low-twenties amid elevated volatility.
Elevated volatility with sharp moves from late
Sentiment & News
Key News Insights:
- •4M ICLs
- •Earnings miss
- •Large insider buys
STAAR beat a major adoption milestone (4M ICLs) and saw heavy insider buying yet missed Q4 EPS and announced interim co-CEOs, signaling long-term commercial strength but near-term execution and leadership risks.
The mix of strong commercial traction and visible insider conviction may support the stock long term, but near-term volatility is likely as investors digest the earnings shortfall and leadership transition
Similar Companies in Healthcare
Other companies in the same sector with AI ratings